Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,466
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
AGGREY DHABANGI
ID:
Hemolytic Disease of the Newborn in Uganda: Burden and Clinical Characteristics (Short title: HDN in Uganda)
REFNo: HS1089ES

To determine the prevalence of HDN due to RhD among newborn infants with jaundice admitted to Kawempe National Referral hospital in Uganda.
 Uganda 2021-02-12 2024-02-12 Medical and Health Sciences Non-degree Award
Peter Elyanu James
ID: UNCST-2021-R013210
 PREVALENCE AND RISKS ASSOCIATED WITH METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS LIVING WITH HIV IN UGANDA. A PILOT STUDY
REFNo: HS1128ES

i To determine the prevalence of MetS among children and adolescents living with HIV in Uganda.
ii To identify risks factors for the development of MetS in children and adolescents living with HIV.

Uganda 2021-02-12 2024-02-12 Medical and Health Sciences Non-degree Award
Abner Tagoola
ID:
A phase 2b study to Evaluate the safety and efficacy of IMR-687 in subjects with sickle cell disease.
REFNo: HS1092ES

1. To evaluate the fetal Hb (Hbf) response to IMR-687 versus placable.

2. To evaluate of IMR-687 versus placable
 Uganda 2021-02-11 2024-02-11 Medical and Health Sciences Non-degree Award
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
 A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
REFNo: HS1150ES

Objectives:
Primary Objectives
• To evaluate the fetal hemoglobin (HbF) response to IMR-687 versus placebo
• To evaluate the safety of IMR-687 versus placebo Seconduy Efficacy Objectives
• To evaluate the effect of IMR-687 versus placebo on HbF-associated biomarkers
• To evaluate the effect ofIMR-687 versus placebo on indices of red cell hemolysis
• To evaluate the effect ofIMR-687 versus placebo on indices of white blood cell (WBC) adhesion
To evaluate the effect of IMR-687 versus placebo on the incidence of vaso-occlusive crises (vocs)
• To evaluate the effect of IMR-687 versus placebo on quality of life measures Pharmacokinetic•Óbjectives
• To evaluate the PK ofIMR-687 and any major circulating metabolites
Exploratory Efficacy Objectives
To evaluate the effect of IMR-687 versus placebo on changes in red blood cell (RBC) characteristics and total Hb e To evaluate the effect of IMR-687 versus placebo on renal function
• To evaluate the effect of IMR-687 versus placebo on indices associated with cardiovascular pathophysiology and ischemic stroke risk

 Uganda 2021-02-11 2024-02-11 Medical and Health Sciences Non-degree Award
Casim Tolo Umba
ID: UNCST-2021-R012658
 Action Towards Reducing Aquatic snail-borne Parasitic diseases (ATRAP)
REFNo: NS128ES

The main objective of the project is to improve Health through the prevention and mitigation of risks that originate at the interface between humans, animals and the environment. In this project we want to increase the capacity to prevent infections by snail-borne diseases in western Uganda. The strategic objectives are as follows:
1. To strengthen scientific research capacity.
2. To strengthen physical and virtual diffusion of scientific research
results to the larger scientific community
3. To raise awareness about snail borne diseases to the general public.
4. To support good governance, based on the scientific results.
5. To develop synergies and complementary activities among partners through multi-partner governance and coordination


 Uganda 2021-02-10 2024-02-10 Natural Sciences Degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS